IP Library Granted Patent US 7,985,736
Granted Patent B2
US 7,985,736 · App. 11/793,058 · Granted Jul 26, 2011

High throughput screen utilizing newly discovered intramolecular neuronal calcium channel interactions to discover new analgesics

Assignee: The John Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,985,736
App. No.
11/793,058
Granted
Jul 26, 2011
Kind
B2
Abstract

The present invention relates to compositions to treat Ca V 2 disorders. The invention also relates to methods treating Ca V 2 disorders. The invention further relates to kits for treating Ca V 2 disorders in a subject. The invention further relates to methods of identifying novel treatments for treating Ca v 2 disorders in a subject.

Claims (15)

1. A pharmaceutical composition comprising a voltage gated calcium channel modulator comprising an amino acid sequence selected from:

MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSI AQRARTMALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWP (SEQ ID NO: 1); NT B (45-95) KQSIAQRARTMALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWP (SEQ ID NO: 2); or

or NT B (56-95) MALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWP (SEQ ID NO: 3); wherein the modulator is effective to treat ameliorate, reduce or alleviate pain, an analgesic side effect, analgesic tolerance or symptoms thereof and a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 , wherein said composition enhances potency of an opioid agonist.

3. The pharmaceutical composition of claim 1 , further comprising an opioid analgesic.

4. The pharmaceutical composition of claim 3 , wherein the opioid analgesic is morphine, hydrocodone, oxycodone, codeine, fentanyl, alfentanil, hydromorphone, meperidine, methadone, oxymorphone, propoxyphene, or tramadol.

5. An isolated peptide consisting of the amino acid sequence SEQ ID NO:1, SEQ Is NO:2, or SEQ ID NO:3.

6. A pharmaceutical composition comprising a voltage gated calcium channel modulator consisting of amino acid sequence: MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSI AQRARTMALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWP (SEQ ID NO: 1); NT B (45-95) KQSIAQRARTMALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWP (SEQ ID NO: 2); or

or NT B (56-95) MALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWP (SEQ ID NO: 3); wherein the modulator is effective to treat, ameliorate, reduce or alleviate pain, an analgesic side effect, analgesic tolerance or symptoms thereof and a pharmaceutically acceptable excipient.

7. A method to treat, ameliorate, reduce or alleviate pain, comprising: administering to a subject in need thereof a pharmaceutically effective amount of a composition of claim 1 or claim 6 .

8. The method of claim 7 , further comprising administering one or more Gβγ polypeptides.

9. The method of claim 7 , further comprising administering one or more opioid agonists.

10. The method of claim 9 , wherein the opioid antagonist is from about 0.1 mg to about 300 mg.

11. The method of claim 7 , wherein the pain is chronic pain, neuropathic pain, or acute pain.

12. A method for enhancing the potency of an opioid agonist comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 1 or claim 6 .

Assignments (1)
CONFIRMATORY LICENSE Recorded Oct 30, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044634/0301 →
Continuity (2)
Provisional Application 60636017 · Dec 14, 2004
Related Publication 20080279864A1 · Nov 13, 2008